CO4940489A1 - Nuevo metodo de tratamiento cines asociadas a la misma en mamiferos - Google Patents

Nuevo metodo de tratamiento cines asociadas a la misma en mamiferos

Info

Publication number
CO4940489A1
CO4940489A1 CO98040749A CO98040749A CO4940489A1 CO 4940489 A1 CO4940489 A1 CO 4940489A1 CO 98040749 A CO98040749 A CO 98040749A CO 98040749 A CO98040749 A CO 98040749A CO 4940489 A1 CO4940489 A1 CO 4940489A1
Authority
CO
Colombia
Prior art keywords
treatment
thiazolidin
dione
benzyl
cinema
Prior art date
Application number
CO98040749A
Other languages
English (en)
Inventor
Robin Edwin Buckingham
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of CO4940489A1 publication Critical patent/CO4940489A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Un producto para el tratamiento de la diabetes mellitus y lascondiciones asociadas con la diabetes mellitus en un mamífero, cuyo producto comprende administrar una cantidad ====== no tóxica y farmacéuticamente aceptable de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucémico inhibidor de alfa-glocosidasa, a un mamífero que necesita del mismo.1Un producto de acuerdo con la reinvindicación 1, en el que el sensibilizador a insulina es (+)-5-[[4-[(3,4-dihidro-6-hidroxi-2,5,7,8-tetrametil-2H-1-benzopiran-2-il)metoxi]fenil]metil]-2,4- tiazolidindiona (o troglitazona), 5-[4-[(1-metil-ciclohexil)metoxi]bencil]tiazolidin-2,4-diona (o ciglitazona), 5-[4-[2-(5-etil-piridin-2-il)etoxi]bencil]-tiazolidin-2,4-diona (o pioglitazona) o 5-[(2-bencil-2,3-dihidro-benzopiran) -5-ilmetil] tiazolidin-2,4-diona (o englitazona); o una forma farmacéuticamente aceptable del mismo.
CO98040749A 1997-07-18 1998-07-17 Nuevo metodo de tratamiento cines asociadas a la misma en mamiferos CO4940489A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
CO4940489A1 true CO4940489A1 (es) 2000-07-24

Family

ID=10816170

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98040749A CO4940489A1 (es) 1997-07-18 1998-07-17 Nuevo metodo de tratamiento cines asociadas a la misma en mamiferos

Country Status (27)

Country Link
EP (1) EP1001784A1 (es)
JP (1) JP2001510160A (es)
KR (1) KR20010021952A (es)
CN (1) CN1263467A (es)
AP (1) AP2000001735A0 (es)
AR (2) AR016350A1 (es)
AU (1) AU8449098A (es)
BG (1) BG104062A (es)
BR (1) BR9810292A (es)
CA (1) CA2297133A1 (es)
CO (1) CO4940489A1 (es)
DZ (1) DZ2563A1 (es)
EA (1) EA200000140A1 (es)
GB (1) GB9715298D0 (es)
HU (1) HUP0003626A3 (es)
ID (1) ID23804A (es)
IL (1) IL133907A0 (es)
MA (1) MA24608A1 (es)
NO (1) NO20000230L (es)
OA (1) OA11312A (es)
PE (1) PE99499A1 (es)
PL (1) PL338140A1 (es)
SK (1) SK612000A3 (es)
TR (1) TR200000133T2 (es)
UY (1) UY25101A1 (es)
WO (1) WO1999003478A1 (es)
ZA (1) ZA986364B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP1849475A1 (en) 1999-06-21 2007-10-31 Eli Lilly & Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
ATE346613T1 (de) * 2000-01-21 2006-12-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
JP4917712B2 (ja) * 2000-02-24 2012-04-18 武田薬品工業株式会社 併用医薬
CA2401356A1 (en) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Combination drug
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
WO2005041962A1 (en) 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
CN101103993B (zh) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 降糖药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003724A1 (en) * 1991-08-26 1993-03-04 The Upjohn Company Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
AR016350A1 (es) 2001-07-04
BG104062A (en) 2000-11-30
SK612000A3 (en) 2000-07-11
MA24608A1 (fr) 1999-04-01
CA2297133A1 (en) 1999-01-28
PL338140A1 (en) 2000-09-25
JP2001510160A (ja) 2001-07-31
BR9810292A (pt) 2000-09-19
UY25101A1 (es) 2000-12-29
PE99499A1 (es) 1999-12-18
WO1999003478A1 (en) 1999-01-28
KR20010021952A (ko) 2001-03-15
NO20000230D0 (no) 2000-01-17
GB9715298D0 (en) 1997-09-24
DZ2563A1 (fr) 2003-02-15
ID23804A (id) 2000-05-11
HUP0003626A2 (hu) 2001-05-28
HUP0003626A3 (en) 2001-12-28
CN1263467A (zh) 2000-08-16
ZA986364B (en) 2000-01-17
EP1001784A1 (en) 2000-05-24
IL133907A0 (en) 2001-04-30
NO20000230L (no) 2000-01-17
EA200000140A1 (ru) 2000-06-26
AR019724A2 (es) 2002-03-13
TR200000133T2 (tr) 2000-09-21
AP2000001735A0 (en) 2000-01-16
AU8449098A (en) 1999-02-10
OA11312A (en) 2003-10-24

Similar Documents

Publication Publication Date Title
CO5300392A1 (es) Nueva composicion y uso
MY129897A (en) Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
HUP0003876A2 (hu) Tiazolidin-dion-származékok alkalmazása polycystás petefészek szindróma és terhességi diabetes kezelésére
CO4940420A1 (es) Nuevo metodo de tratamiento
CO4940489A1 (es) Nuevo metodo de tratamiento cines asociadas a la misma en mamiferos
EP1593379A3 (en) Uses of PPAR-gamma agonists in neutrophil-induced diseases
NO313226B1 (no) Farmasöytisk sammensetning som omfater en insulinsensitivitetsenhancer i kombinasjon med eninsulinsekresjonsenhancer og anvendelse av disse
NO2963A (no) Anvendelse av forbindelsen 5-[4-[2-(5-etylpyridin-2-yl)- etoksy]benzyl]tiazolidin-2,4-dion (pioglitazone) for fremstilling av et medikament for behandling av svekket glukosetoleranse
CO4940422A1 (es) Novedoso metodo de tratamiento
WO2000076488A3 (en) Use of a ppar agonist for treating type 1 diabetes
US5708012A (en) Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
PE20001428A1 (es) Composicion de liberacion modificada
AR015894A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
AP1600A (en) Combination of a thiazolidinedione and a sulphonylurea for treating diabetes
PE20001239A1 (es) Composicion de un sensibilizador de insulina
NZ522730A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
BR0111536A (pt) Sal de tiazolidinediona para tratamento de diabetes mellitus
BR0112982A (pt) Sal tartarato de derivado de tiazolidinadiona
DK1315724T3 (da) Thiazolidindionderivat og dets anvendelse som antidiabetikum
PE20000881A1 (es) Uso de tiazolidindiona como cardioprotector
NO20075507L (no) Tiazolidindionderivater og deres anvendelse som antidiabetiske midler
BR0017254A (pt) Tratamento e prevenção de condições associadas à resistência cardìaca à insulina
MXPA00003633A (es) Uso de tiazolidinodionas para el tratamiento de la hiperglucemia
HUP0003673A2 (hu) Dioxo-tiazolidinek alkalmazása a hyperglykaemia kezelésére